The U.S. Food and Drug Administration (FDA) granted accelerated approval to blinatumomab (Blincyto) for the treatment of pediatric patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).1

Approval of this supplemental Biologics License Application is based on findings from Study ‘205, an open-label, multicenter, single-arm trial, which assessed the efficacy and safety of blinatumomab among 93 children with relapsed or refractory B-cell precursor ALL.

In May 2016, it was reported that the trial met its phase 2 primary end point of complete remission within the first 2 cycles of immunotherapy.

Continue Reading

Continued approval may be contingent upon verification of clinical benefit in additional studies.

The most common grade 3 or worse treatment-related adverse events among those who received the recommended dose were anemia, neutropenia, febrile neutropenia, thrombocytopenia, and hypokalemia.

Blinatumomab is a bispecific CD19-directed CD3 T cell engager (BiTE®) antibody construct that binds specifically to CD19 expressed on the surface of cells of B-lineage origin and CD3 expressed on the surface of T cells. It is also approved for this indication in adult patients.

RELATED: FDA Approves Ofatumumab With Chemo for Relapsed CLL

Clinicians should be aware that blinatumomab may cause life-threatening or fatal cytokine release syndrome, and neurological toxicities that may be severe, life-threatening, or fatal.                          


  1. FDA approves Blincyto (blinatumomab) for use in pediatric patients with philadelphia chromosome-negative relapsed or refractory b-cell precursor acute lymphoblastic leukemia [press release]. Amgen website. Updated September 1, 2016. Accessed September 1, 2016.